SAN DIEGO, Aug. 20, 2020 /PRNewswire/ — Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary gene engineering platform technologies to create cell and gene therapeutics with the capacity to cur… […]
CARLSBAD, Calif., Aug. 14, 2020 /PRNewswire/ — Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (Qualigen or the Company) today announced business highlights and financial results for the fiscal year 2021 first quarter, ended June 30, 2020.
Business hig… […]
Completion of Dosing in Phase 1 Multiple Ascending Dose Study (“MAD”) of RGLS4326 in Healthy Volunteers for Autosomal Dominant Polycystic Kidney Disease (“ADPKD”)FDA Orphan Designation of RGLS4326 for ADPKDAppointment of Denis Drygin, Ph.D., as Chief S… […]
SAN DIEGO, Aug. 11, 2020 /PRNewswire/ — Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on developing products to diagnose and treat life and organ threatening diseases, today reported financial results for its fi… […]
Successful completion of $300 million initial public offering; cash and cash equivalents of over $350 million as of June 30, 2020Strengthened leadership team with additions of Michael MacLean as Chief Financial Officer and Jae Kim, M.D., as Chief Medic… […]
– Reports First Quarter of Expected Sustainable Profitability and Maintains 2020 Guidance of $230 to $245 Million in Revenues and $0.60 to $0.75 Earnings Per Share — Two U.S. FDA Approvals and One EMA Approval Received by Partners for Products Utilizi… […]
SAN DIEGO, Aug. 6, 2020 /PRNewswire/ — Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results and a corporate update for the second quarter ended June 30, 2020.
“Mirati is working to d… […]
SAN DIEGO, Aug. 5, 2020 /PRNewswire/ — Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best–in-class treatments to address some of the most important unmet p… […]
– Advancing Precommercial Activities in Preparation for Phexxi(TM) Commercial Launch in September 2020 — Pivotal Phase 3 Trial of EVO100 for Prevention of Chlamydia and Gonorrhea on Track for Q4 2020 Initiation — Management to Host Conference Call Tu… […]
Conference call scheduled for 4:30 p.m. ET today- Enrollment Continues in Phase 2b VOYAGE Study of VK2809 in NASH; New Data from 12-Week Phase 2 Trial to be Highlighted at EASL- IND Filed for VK0214 in X-ALD; Phase 1 Trial Expected to Begin Q3 2020- Ba… […]